JPMorgan Chase & Co. now owns 1,465,914 shares of the biopharmaceutical company's stock worth $10,452,000 after buying an additional 44,828 shares during the period.
05/31/2017 - Amicus Therapeutics, Inc. had its " rating reiterated by analysts at Chardan Capital. Robert W. Baird reissued an "outperform" rating and set a $12.00 target price (up previously from $10.00) on shares of Amicus Therapeutics in a research note on Wednesday, May 17th. State Street Corp raised its position in shares of Amicus Therapeutics by 12.2% in the fourth quarter. Mean recommendation is rated on a 1 to 5 scale. (FOLD) stock price comparison to its moving averages, shares of company are 50.68% away from the 50-day moving average and 32.63% away from 20-day average.
Amicus Therapeutics, Inc. (FOLD)'s RSI (Relative Strength Index) is 82.43.
Amicus Therapeutics stock vaulted higher by 26% in the wake of good news from the U.S. Food and Drug Administration. The stock's market cap is $1.85 billion.
Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Tuesday, May 9th.
So the company lags the analysts estimate by $-0.03/share showing a surprise of -8.3%. The firm had revenue of $4.20 million for the quarter, compared to analysts' expectations of $4.16 million. Amicus Therapeutics's revenue was up 50.0% compared to the same quarter previous year. On average, equities analysts predict that Amicus Therapeutics will post ($1.45) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Stock Observer and is the property of of Stock Observer. If you are viewing this report on another website, it was illegally stolen and republished in violation of USA and worldwide trademark & copyright laws. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/07/10/amicus-therapeutics-inc-fold-stake-boosted-by-palo-alto-investors-llc-updated-updated.html. The stock was sold at an average price of $8.00, for a total value of $239,312.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. They now have a Dollars 10 price target on the stock. Closely-held shares are those owned by insiders, major shareholders and employees, while restricted stock refers to insider shares that can not be traded because of a temporary restriction such as the lock-up period after an initial public offering. The disclosure for this sale can be found here. Following the completion of the sale, the insider now directly owns 474,438 shares of the company's stock, valued at $3,795,504.
Want to see what other hedge funds are holding FOLD? Rockefeller Financial Services Inc. purchased a new position in Amicus Therapeutics during the first quarter valued at $136,000.
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now. and Amicus Therapeutics wasn't one of them! The current trading volume of 1.45 sits 78.62% lower than the past 3 month's readings, indicating near-term traders have been less active toward FOLD than usual of late.
July 11, 2017Amicus Therapeutics (FOLD) plans to submit a new drug application (NDA) to the U.S. FDA for the oral precision medicine migalastat for Fabry disease in the first quarter of 2017.
American International Group Inc. boosted its position in Amicus Therapeutics, Inc. Victory Capital Management Inc. raised its position in shares of Amicus Therapeutics by 21.7% in the first quarter.
Jay Barth, M.D., Chief Medical Officer of Amicus Therapeutics, stated, "The data from our clinical trials, including the two largest pivotal studies ever completed in Fabry disease, have already supported authorization s for migalastat in the EU, Israel and Switzerland, as well as our pending regulatory submissions in Japan, Canada and Australia".